Immunome Inc.

Immunome is a clinical-stage biotechnology company focused on discovering, designing, and developing targeted oncology therapeutics. Its pipeline centers on antibody-drug conjugates (ADCs), gamma secretase inhibitors, and radioligand therapies designed to treat solid tumors and hematologic malignancies. Primary investigational programs include varegacestat for desmoid tumors, IM-1021 for ROR1-expressing cancers such as B-cell lymphomas, and IM-3050 for fibroblast activation protein-positive solid tumors. In addition, the firm is advancing preclinical ADC candidates supported by its proprietary HC74 topoisomerase 1 inhibitor payload and linker technologies. The company's end users and customers encompass cancer patients, healthcare providers, and clinical trial participants seeking targeted oncologic treatments.

Immunome conducts clinical development on an international scale, running global registrational studies across clinical trial sites located in North America, Europe, Asia, and Australia. The company also utilizes external clinical-stage supply chains involving third-party diagnostic and radiotracer partners. The provided excerpt does not disclose the location of the company's corporate headquarters, operational facilities, or total employee headcount.

Summary of the business section of Immunome's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 177 full-time employees, 133 of whom were engaged in research and development activities.”